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Abstract Pharmacokinetic/pharmacodynamic (PKPD)
modeling is important in the design and conduct of clinical
pharmacology research in children. During drug develop-
ment, PKPD modeling and simulation should underpin
rational trial design and facilitate extrapolation to investi-
gate efficacy and safety. The application of PKPD mod-
eling to optimize dosing recommendations and therapeutic
drug monitoring is also increasing, and PKPD model-based
dose individualization will become a core feature of per-
sonalized medicine. Following extensive progress on
pediatric PK modeling, a greater emphasis now needs to be
placed on PD modeling to understand age-related changes
in drug effects. This paper discusses the principles of
PKPD modeling in the context of pediatric drug develop-
ment, summarizing how important PK parameters, such as
clearance (CL), are scaled with size and age, and highlights
a standardized method for CL scaling in children. One
standard scaling method would facilitate comparison of PK
parameters across multiple studies, thus increasing the
utility of existing PK models and facilitating optimal
design of new studies.
Key Points
Pharmacokinetic/pharmacodynamic (PKPD)
modeling is important in the design and conduct of
clinical pharmacology research in children, and the
so-called ‘population’ approach is suitable for rich or
sparse data in terms of the number of samples per
subject
The utility of pediatric PK models can be increased
by using a standardized approach to scaling: a
suggested method for scaling clearance (CL) is a
combination of allometric weight scaling with a
sigmoid function to account for organ maturation.
This should be used a priori, as a ‘base’ approach,
allowing the effects of age and size to be delineated
from other patient-specific factors, such as disease
state and organ (dys)function
When determining the pediatric dose, instead of
directly scaling the dose from adults to children, the
pediatric PK parameter estimates should be obtained
from a PK model with a standardized scaling
approach in order to avoid the use of arbitrary cut-off
values (of age/weight) according to a specific (non-
standardized) CL-scaling formula
Significant progress has recently been made on
pediatric PK modeling; a greater emphasis now
needs to be placed on PD modeling to understand
age-related changes in drug effects
PKPD model-based dose individualization is
becoming increasingly popular as the age of
personalized medicine dawns
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1 Introduction
During the evolution of modern drug development, pedi-
atrics and neonatology were largely neglected, rendering
children and infants ‘therapeutic orphans’ [1, 2]. However,
in recent years there has been an increase in research
activity to support the development of evidence-based
pharmacotherapy for children stimulated by the advent of
new legislation to mandate licensing for new medicinal
products in this population [3, 4]. Pharmacokinetic/phar-
macodynamic (PKPD) modeling and simulation (M&S)
play a pivotal role in pediatric drug development through
supporting rational trial design and increasingly replacing
traditional trials through extrapolation of efficacy and
safety [5–7]. Furthermore, the application of PKPD mod-
eling to optimize dosing recommendations and therapeutic
drug monitoring (TDM) strategies is also increasingly
recognized. Historically, children were originally treated as
‘small adults’, i.e. the dose was simply scaled down per
linear weight, leading potentially to overdosing in very
small children, especially neonates, as their kidneys and
liver were not yet fully developed, often resulting in slower
drug elimination [8]. As awareness of developmental
pharmacology subsequently expanded, the physiological
differences in drug handling between children and adults
were emphasized, leading to the notion that ‘children are
not small adults’ [9]. However, rather than dichotomizing
adult and pediatric patients, recognition that maturation is a
continuous process has since led to acknowledgment of the
need to quantify differences and understand similarities
across the age range with appropriate scaling. This paper
discusses the principles of PKPD modeling in the context
of pediatric drug development, and highlights the impor-
tance and benefits of using one standardized method for
scaling clearance (CL) in children.
2 Pediatric Drug Development: Background
and Legislation
In many regions, including the US and Europe, regulations
requiring pharmaceutical companies to demonstrate both
safety and efficacy of their products prior to marketing
were introduced following the tragic events relating to
thalidomide use during the 1960s [10]. Despite the fact that
infants were the main victims of thalidomide’s teratogenic
effects, the resultant drug legislation was not specifically
targeted towards children or neonates [1]. This meant that
unlicensed and off-label use of medicines has remained
unavoidably commonplace in pediatrics and neonatology,
together with its associated risks [11–14]. However, in
recent years, specific legislation has come into effect that
enshrines pediatric medicines research in law for new
medicinal products licensed within the relevant jurisdic-
tions [15, 16]. Some key landmarks in these developments
are outlined in Table 1.
In both the European Union (EU) and the US, the
introduction of such legislation has necessitated the con-
sideration of children and neonates earlier during the drug
development process. During the last 20 years, the use of
M&S to support pharmacological research in children, as
well as adults, has also advanced significantly. The tech-
niques of M&S may be applied in various contexts and are
not solely limited to PKPD studies (where they are often
known as pharmacometrics); these techniques are dis-
cussed further below. It is important to note that the
applications and benefits of M&S in drug development and
postmarketing drug research are often at risk of being
underutilized [17], especially in circumstances when there
may be limited expertise or if there is ineffective dialogue
between those specialized in modeling (e.g. ‘pharmaco-
metricians’ [18, 19]) and those directly involved in patient
care, i.e. clinicians and pharmacists. Fortunately, the ben-
efits of applying quantitative pharmacological methods in
clinical practice are now more widely appreciated [20], in
addition to their key roles in research and drug develop-
ment [21–25]. To reflect this, there is also a growing
number of experts in M&S within regulatory agencies
[26–28].
2.1 Extrapolating the Dose from Adults to Children
Before considering the pediatric population during drug
development, PKPD data are normally first available from
adult subjects, either healthy volunteers and/or patients.
This then generates questions surrounding the extrapolation
of PKPD information to children, regarding when one can
appropriately use extrapolation techniques [29] and what
information can be safely extrapolated.
Extrapolation can be defined as [abbreviated] ‘‘Extend-
ing information and conclusions available from studies in
one or more subgroups of the patient population (source
population) […] to make inferences for another subgroup
of the population (target population), or condition or pro-
duct, thus reducing the need to generate additional infor-
mation […] to reach conclusions for the target population
[…]’’ [30].
Before undertaking extrapolation exercises, various
distinct aspects of pharmacology must be considered,
including the following.
1. Pharmacokinetics: Absorption, distribution, metabo-
lism, elimination (ADME), and the influence of
developmental pharmacology and ontogeny on the
drug’s PK profile in children of different ages. The
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impact of comorbidities, e.g. renal failure [31], on drug
disposition may also need to be evaluated, where
relevant.
2. Pharmacodynamics (including both efficacy and tox-
icity): Consideration of host developmental and recep-
tor pharmacology, which can affect both the desired
drug effect, through the principal mode of action, and
any off-target effects, which may be desirable (e.g. the
anti-inflammatory activity of macrolide antibiotics
[32]), neutral (i.e. of no clinically important conse-
quence), or toxic. When the target receptor is in
another organism, e.g. the drug target located within
the pathogen in the case of anti-infective therapies,
consideration must also be given as to whether the
target pathogen’s resistance profile is likely to be the
same in neonates and children as in adults.
3. Formulations: Pediatric age-appropriate, formulation-
related issues should be addressed as early as possible
[33], with consideration of a number of factors such as
any potential for excipient-related toxicity [34, 35],
and also palatability and the development of child-
friendly dosage regimens where feasible, both of
which will affect compliance in children [36–38].
M&S can contribute to each of the assessments outlined
above; ranging from dose selection for neonatal/pediatric
clinical studies [39], to investigating the impact of altered
dosing regimens that would fit in better with a child’s daily
routine. Thus, the appropriate use of M&S for extrapola-
tion approaches is of particular significance in pediatric
drug development [40].
For determining when extrapolation is or is not appro-
priate, a useful point of reference is the US FDA Pediatric
Study Decision Tree, shown in Fig. 1 (adapted), which has
been developed for supporting decision making regarding
extrapolation during pediatric drug development [41, 42].
This decision tree highlights the need to evaluate dif-
ferent issues, including the following.
1. Natural history of disease progression in children/
adults, and response to therapeutic intervention.
2. Likely exposure–response profile: Is it sufficient to
simply target the same drug exposure (e.g. with respect
to the area under the curve (AUC) in the PK profile,
once this has been scaled appropriately; see further
details below)?
3. Suitability of the pharmacodynamic measures and
whether these are applicable to children: Is the PKPD
index likely to be the same? For example, during
antimicrobial therapy, typical PKPD indices, such as
the peak concentration (Cmax) for aminoglycoside
therapy, are used in both adult and pediatric popula-
tions [43, 44], but, for some medications/conditions
(such as pulmonary hypertension in neonates [45]),
different pediatric PD measures are required.
The science of extrapolation is a rapidly evolving area,
with many aspects that warrant detailed research
[42, 46–49]. In future, it is likely that there will be further
guidance about related issues, such as the appropriateness
of extrapolation of data between agents within the same
therapeutic class, and how to extrapolate from in vivo
models to neonates for conditions that do not have a
counterpart within the adult population [50]. Overall,
extrapolation should now be viewed as an ethical require-
ment for pediatric drug development since it can reduce the
chance of undertaking unnecessary research and support
the design of those pediatric studies that are required [42].
Accordingly, this important topic has been the focus of
Table 1 Key landmarks in pediatric medicines regulation
Year Regulation Impact
1997 US FDA Modernization Act (FDAMA) This act presented the financial incentive of an additional 6 months of market
exclusivity to companies undertaking required pediatric studies [15]
1998 US FDA Pediatric Rule This rule permitted companies to label medicines for use in children based on
extrapolation of efficacy from adult trial data, together with pediatric PKPD and
safety data [160]
2002
(and
2007)
US Best Pharmaceutical for Children Act
(BPCA)
Framework for pediatric research in both on- and off-patent drugs [161]
2003 US Pediatric Research Equity Act (PREA) Sponsors required to undertake clinical studies in children for new medicines and
biological products [161]
2007 EU Pediatric Regulation Introduction of new legislation in the European Union mandating pediatric medicines
research for new medicinal products [16]
2012 US Food and Drug Administration Safety
and Innovation Act (FDASIA)
BPCA and PREA became permanent in US Law [162]
PKPD pharmacokinetic/pharmacodynamic
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recent new regulatory documents from both the European
Medicines Agency [51] and the International Council on
Harmonization [52].
2.2 Different Levels of Evidence Required
In different circumstances, varying levels of PKPD and
safety data may be required, depending on the particular
drug concerned and the availability of existing, relevant
data in pediatric and neonatal populations. It is important to
assess both the quantity and quality of the PKPD data that
are available in particular pediatric populations [53]. There
are a number of regulatory guidelines that provide advice
to pharmaceutical companies on these topics (for example,
see [53–58]). Some key issues can remain in the ‘gray’
areas; for example, the best way to do sample size calcu-
lations for pediatric PKPD studies that will use population
modeling for the analysis. Previously, Tam et al. investi-
gated the sample size required to generate robust PK pre-
dictions when using population modeling with Monte Carlo
simulations to predict antimicrobial PK variability [59]. To
obtain reasonably robust predictions, it was recommended
that a non-parametric model derived from a sample popu-
lation size of at least 50 subjects was needed as the input
information [59]. However, limited data are currently
available to support evidence-based target setting within
specific subpopulations, such as neonates born at varying
stages of prematurity and with varying degrees of organ
dysfunction. Early consultation with pediatric or neonatal
clinical pharmacologists and pharmacists is advisable
during the protocol development stage to address these
challenges. Pragmatic considerations are also important to
ensure the feasibility of study targets, with consideration of
whether they are realistically achievable within the desired
time frames, as recruitment rates into pediatric trials (in-
cluding simple PK studies) are often surprisingly low
[60, 61]. The FDA have issued specific guidance on
pediatric PK study sample size calculation as follows:
‘‘The study must be prospectively powered to target a 95%
confidence interval (CI) within 60 and 140% of the geo-
metric mean estimates of clearance and volume of distri-
bution for DRUG NAME in each pediatric sub-group with
at least 80% power’’ [62], and Stockmann et al. published
recommendations on how to undertake such calculations
[63]. It is important to recognize that such sample size
calculations will inevitably be affected by uncertainty of
the expected pharmacokinetic parameters in the target
population, and therefore adaptive optimal designs may
have a role to play in target refinement during study
delivery [64]. Sample size might also depend on the rich-
ness of the data, and, in studies where rich sampling is
usually not possible (e.g. neonatal studies), optimal design
can prove useful by providing the most informative time
points for sampling, thus reducing the number of samples
required per subject enrolled [65]. Using optimal design to
identify the most informative sampling times in each
pediatric age group can, at the same time, also help to
increase the power of the PKPD analysis.
Fig. 1 Decision tree for pediatric studies. Adapted from Dunne et al. [42]. PKPD pharmacokinetic/pharmacodynamic
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3 Rationale for Using Modeling
There are numerous advantages to using a model-based
approach over the (traditional) data summary approach (i.e.
calculate AUC, Cmax, etc) for PK or PD studies in children
[66]. For example, non-linear mixed-effects modeling
facilitates the analysis of sparse, unbalanced datasets, which
are common in neonatal and pediatric research settings,
where each individualmay only contribute a small number of
samples, and sample timing/number of samples can vary
between patients—as, for example, in studies with oppor-
tunistic sampling [23, 67, 68]. Furthermore, models can
incorporate factor-relevant covariates, such as age and
weight, which enable us to evaluate the developmental dif-
ferences between adults and children, in addition to ontogeny
and pharmacogenetic factors [23]. The developedmodel can
also account for the whole concentration–time course, and
hence can readily be used as a link with the effect (PD).
A detailed description of the statistical and mathemati-
cal aspects of PKPD modeling is beyond the scope of this
review, but a brief summary of typical modeling methods
for analyzing PKPD data is provided in Table 2 [67].
4 Specific Issues in Pediatric Pharmacokinetic/
Pharmacodynamic (PKPD) Modeling
4.1 Scaling of Pharmacokinetics
4.1.1 Different Approaches for Scaling Pharmacokinetics
Children, especially infants, are smaller, weigh less, and
have a higher proportion of total body water and lower
proportion of body fat compared with adults. Furthermore,
key organ function, specifically kidney and liver function,
is immature in newborns and infants, resulting in a lower
glomerular filtration rate (GFR) and a distinct hepatic
enzyme activity profile. Membrane-bound drug trans-
porters also vary with age [69]. These numerous physio-
logical differences between adults and children,
particularly infants, contribute to PK processes, and con-
sequent age- and size-related differences in PK parameters
[70]. Therefore, PK parameters cannot simply be scaled
linearly from adults to children; instead, approaches such
as allometric scaling, physiologically-based pharmacoki-
netic (PBPK) models [71], and systems pharmacology
modeling [72] should be used [73].
PBPK models are represented by a complex system of
equations with parameters that incorporate biological
knowledge of physiological blood flows, anatomical organ
structures, and also tissue and organ volumes [74]. PBPK
models can be used to predict first-in-man drug doses (prior
to human exposure) [75], first-in-children doses [76], and,
more recently, for drug–drug interaction studies [77], but
have also been suggested for scaling PK to children
[78, 79]. If the aim of a PBPK model is extrapolation to the
pediatric population, it must either firstly describe the adult
data well and include data on all developmental changes
affecting drug pharmacokinetics [80, 81], or, alternatively,
an existing PBPK model for children of a certain age and
medical condition can be used, together with the physico-
chemical properties of the studied drug. However, extrap-
olating across all age groups might be difficult for some
physiological spaces, for example brain and bone marrow
[80]. It can also be challenging to obtain sufficient in vitro
data for some compounds, which could then lead to poor
Table 2 Overview of core pharmacokinetic analytical methods [67]
Method Description Comments
Naive pooled data
approach
All PK data from the study are pooled and analyzed as if
from one individual
The analysis does not incorporate the fact that the data arise
from individuals with between-subject variability, and can
give biased parameter estimates; it can be used in
unbalanced study designs but will overestimate variability
and can lead to biased parameter estimates
Naive average
data approach
The mean drug concentration at each time point in the PK
study is calculated, based on the data at that time point
contributed by all participants. The mean value at each
sampling time is then used to estimate the PK parameters
of interest
This simplistic approach is popular but is unreliable and
limited because it does not consider inter- or
intraindividual variability, and therefore underestimates
variability. It is only suitable for a balanced study design
Two-stage
approach
The PK parameters are first estimated for each individual,
then the variance of these parameter estimates is calculated
This method is attractive because it is mathematically
straightforward, but requires rich individual-level data
Non-linear mixed
effect modeling
(NLME)
All study data are fitted simultaneously in one model, but the
PK parameters are able to vary between individuals
This approach has become standard practice because it
provides unbiased parameter estimates through
simultaneous quantification of parameter-level
interindividual variability, and observation-level residual
variability
PK pharmacokinetic
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predictive performance [82]. Some authors have fitted
PBPK models to PK data to overcome this [83, 84];
however, this approach is not yet widely used in pediatric
research, but is growing in application and can be used to
update or refine the PBPK model. Although the validation
requirements for PBPK models are not yet as well defined
as, for example, those for population PKPD modeling, the
average fold error is often used as a guiding metric for
validation [85, 86].
Systems pharmacology models are based on a network
of nodes (or functional elements), with functional interac-
tions between them. Recently, these models have been
suggested to be useful for describing disease progression
and complex drug action patterns [72].
An alternative to extrapolating PK from adults to chil-
dren is to perform model-based meta-analysis of existing
pediatric data [73], or an empirical analysis of the observed
pediatric drug PK data [73], where characteristics of
patients can be used as covariates to help explain and
describe the ontogeny of a PK parameter. These two
approaches are especially useful when, for example,
designing a new clinical trial (to e.g. test a new dosing
regimen) in a similar pediatric population. Since pharma-
cological effects of many drugs are driven by drug expo-
sure (AUC), which is indirectly proportional to CL, we
usually focus on scaling CL. As CL changes as humans
grow and age/mature, models need to account for these
two, correlated processes.
For drugs that are orally administered, the influences of
age-appropriate formulations and developmental differ-
ences in bioavailability on pharmacokinetics also need to
be considered, which are discussed in detail elsewhere
[87]; these factors can also be taken into account with
model-based approaches to investigate pediatric PK.
4.1.2 Body Size
Almost 70 years ago, Crawford et al. noted that using body
surface area (BSA) is preferred over linear weight for
predicting doses [88]. Decades later, it was suggested that a
so-called allometric approach (Eq. 1), which scales meta-
bolic processes with body size, could also be used to
explain changes in drug CL [89]:
yi ¼ a WTbi ; ð1Þ
where yi is the individual subject’s body function of
interest (that is being predicted), WT is the individual’s
body weight in kilograms, a is the allometric constant,
which assumes the value of y when WT = 1 kg, and b is
the allometric exponent (b \ 1 indicates that the body
function increases slower with body size than weight).
Hereafter, we use the term allometric scaling to refer to
allometric scaling of CL.
Historically, although studied for almost a century, there
has been no agreement on which value of the allometric
exponent to use, but generally values between 0.63 and
0.78 have been suggested. For example, in the 1930s,
Benedict proposed the use of 0.67 since it was found that
the basal metabolic rates scale best with BSA, which is
approximately WT0.67 [90]. Around the same time, Kleiber
looked at 13 different species of mammals with a wide
weight range (0.15–679 kg) and concluded that the value
of the allometric exponent should be 0.75 [91]. However,
he also noticed that the value of the exponent (0.67 or 0.75)
only altered predictions if the difference between the sub-
jects’ weight was at least ninefold [92]. More recently,
GFR was found to scale with weight raised to the power of
0.63 [93], and hepatic blood flow with WT0.78 [94]. In a
recent meta-analysis of almost 500 PK studies, McLeay
et al. [95] found that, when estimated, the median value of
the allometric exponent was 0.65 (range - 1.2 to 2.2), but
the most common fixed value was 0.75 (also most often
used in pediatric PK studies). Although the allometric
exponent remains a highly controversial topic, the use of a
fixed allometric exponent of 0.75 (combined with a mat-
uration function for younger children) was also supported
by our recent study, which compared 18 approaches for
scaling CL [96].
4.1.3 Size and Maturation
Using allometric models alone, which only account for
size-related CL changes, is not sufficient [79, 97], partic-
ularly for neonates and infants, since CL is frequently
lower than expected in these pediatric populations due to
the physiological immaturity of their organs [98]. There-
fore, age also needs to be taken into account, especially
when analyzing data from neonates as their organ functions
change very rapidly [70]. Taking both size and age into
account in model development can help capture CL
changes across the whole pediatric age range.
There has been much heated debate about how best to
account for both size and maturation in pediatric PK
studies [71, 82, 99]. While we know that ‘‘all models are
wrong, some are useful’’ [100], a wide range of different
approaches can impede our ability to compare parameters
between studies of the same (or similar) drugs, by creating
added complexity. Importantly, using a standardized
method for parameterizing size and age across studies
could aid extrapolation, improve study design, and poten-
tially allow for smaller sample sizes. In a recently pub-
lished paper, we identified the various approaches taken to
scaling CL, and provided a direct comparison of these
methods using the same dataset for two drugs with
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different routes of elimination, specifically glomerular fil-
tration and hepatic metabolism [96]. In light of the results,
and in the knowledge that weight and age are highly cor-
related, albeit with the correlation varying at different ages,
we recommend using a combination of allometric weight
scaling with a sigmoidal maturation function (Eq. 2) to
describe the changes in CL due to age and weight. By
adding age into the model one can estimate the deviation
(especially in the younger group) from CL, predicted using
only the biological prior knowledge of allometric scaling
(i.e. size).
CLchild ¼ CLadult  WTchild
70
 b
 PMA
Hill
PMAHill50 + PMA
Hill
; ð2Þ
where CLchild is the predicted drug CL for a studied child,
CLadult is the typical CL for a 70 kg adult, b is the allo-
metric exponent that can be estimated, but fixing to 0.75 is
advocated (especially if the WT range in the studied pop-
ulation is small), PMA is the child’s postmenstrual age
(usually in weeks), PMA50 is the PMA when CL has
reached 50% mature, and Hill is the sigmoidicity/shape
parameter.
Using postmenstrual age to account for preterm neo-
nates is important, although it should be noted that addi-
tional postnatal age scaling may be needed due to
physiological changes at birth regardless of gestational age
[101]. Additionally, it is sometimes also necessary to add a
so-called organ function, accounting for the difference in
the organ function between healthy and diseased; for
example, a function including serum creatinine concen-
tration in the case of a renally excreted drug (or another
suitable biomarker reflecting renal function) [8, 101].
Including a standardized parameterization for age and
size in PKPD models reported in publications would enable
comparison of parameters across studies of the same or
similar compounds. When planning new studies, drug-,
organ- or enzyme-specific maturation models can be used
in the prediction of expected CL to a similar pediatric
population. Such models can also be used when fitting data,
and literature models may be particularly useful in this
context when small age ranges are studied [101–103]. In
this case, the maturation model may be fixed or introduced
as a Bayesian or ‘frequentist’ prior. This approach to
extrapolation requires further research and is likely to be
limited by drug physicochemical properties.
4.2 Dose Selection in Pediatric Studies:
Extrapolation and Prediction
Determining a first pediatric dose is difficult because one
needs to take into account efficacy as well as safety since it
would usually not be considered ethical to give a child an
ineffective dose (microdosing studies excepted [104]).
Ideally, a PK study in the pediatric population would be
used to define a pediatric dose, but this is not always
possible [82, 105]. The pediatric dose is thus usually pre-
dicted by down-extrapolating the adult dose [106]. His-
torically, this has been done with empirical methods: linear
weight scaling or non-linear allometric weight scaling
(Eq. 3) [8, 107]:
Dosechild = Doseadult  WTchild
70
 b
; ð3Þ
where WTchild is the weight of a child in kilograms. No
single value of b is suitable across the whole pediatric age
range [82, 106], without also accounting for maturation
[108]. Scaling CL linearly with weight from adults to
neonates while ignoring maturation can lead to serious
adverse reactions, such as ‘gray baby syndrome’ [109], and
kernicterus [110], which occurred after the administration
of chloramphenicol and sulphonamides to infants.
Thus, now that scaling for both size and maturation is
well established (as outlined above—although there may
be a time lag before it is widely adopted), a more sophis-
ticated approach can be used to account for the rapid
increase in weight and the concurrent changes in organ
function maturation. Instead of scaling the dose directly,
we can scale PK in order to obtain pediatric PK parameter
estimates and determine the dose for a child of any age or
weight, without the need for arbitrary cut-off values for
either covariate (as typically specified in the non-stan-
dardized formulae for scaling CL) [8]. As mentioned
above, there are strong arguments to advocate that adult CL
should ideally be scaled to children using a standardized
approach [96]. Using a model-based approach to guide
dosing in children has previously been suggested
[111, 112], and efforts to develop and validate individu-
alized dosing software are ongoing in both children [113]
and adults [114]. It should be noted that caution is required
when extrapolating across populations if the covariates
within the target population lie outside the range included
within the model development dataset as parameter–co-
variate relationships can change in different pediatric
populations [47]. In such instances, where this caveat is
unavoidable, it may be helpful to combine ‘bottom-up’
approaches (e.g. PBPK) and ‘top-down’ approaches (e.g.
population PK) to first test whether the different methods
produce reasonably similar results [115].
Obese children may also need to have their dose
adjusted for certain agents [116], with lean body weight
being suggested as the preferred body size descriptor in this
population [117, 118]. Another possible size descriptor
could be fat-free mass (FFM). A model for predicting FFM
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from a child’s weight, age, sex, and body mass index
(BMI) has recently been developed [119]; however, this
model only included data from children[ 3 years of age,
and therefore cannot be used for neonates and infants.
Furthermore, BMI is unsuitable for use in neonates. More
studies focusing on obese and overweight children are
needed before the best body size descriptor can be defined
and before concluding whether dose adjustment is clini-
cally necessary [116, 117].
Standardized parameterization for the scaling of CL in
pediatric PK models is likely to remain a topic of some
controversy, but, in light of the numerous benefits it con-
fers, we believe its importance is paramount. However, we
are not suggesting that pharmacokinetic modeling analyses
should employ only this method in isolation, but would
instead encourage analysts to publish their results using the
standardized parameterization, in addition to the results
using other parameterizations that they identify as provid-
ing a good fit to the data. This will enable ongoing collation
of data about the performance of this method for drugs with
different physicochemical properties and distinct pharma-
cokinetic profiles.
4.3 Scaling of Pharmacodynamics
While much recent emphasis has been placed on scaling
PK, methods for investigating maturation and scaling of
pediatric PD have frequently been neglected. This might be
attributed to the fact that drug effect is more difficult to
measure and evaluate, especially in neonates and infants
[8]. PD endpoints can vary widely depending on the dis-
ease, therefore there will never be a single, unified method
for PD scaling. For example, the GABAergic inhibitory
system within the central nervous system is immature in
neonates compared with adults, causing benzodiazepines to
paradoxically exacerbate seizures, especially in premature
newborns [120, 121]. With reference to the immune sys-
tem, thymic output of T cells is higher in children com-
pared with adults, with a peak in the thymic output at
approximately 1 year of age [122]. Advanced knowledge
of PD maturation might be anticipated in anesthesia, where
drug effect is monitored in real time. It has long been
known that for inhalational anesthetics, the alveolar con-
centration required for 50% of patients not to react to
surgical incision initially rises, then falls with age [123]. In
contrast, for propofol, Peeters et al. found that the target
concentration in infants is the same as in adults, and dose
differences were due to PK maturation [124]. In view of the
extensive differences in PD between adults, children, and
neonates, a greater use of PD modeling—rather than just
simple extrapolation—is needed between these populations
in order to reach and verify an efficacy target equivalent to
adults [125].
4.4 Model Evaluation
A model should always be evaluated before it can be used
for extrapolation [126]; several internal and external vali-
dation methods can be employed for this purpose. Internal
methods include diagnostic goodness-of-fit plots, such as
observed values of dependent variables plotted against
population and/or individual predicted values [127, 128].
The distribution of the residual errors should also be
examined to confirm whether they are normally distributed;
conditional weighted residual errors can be plotted versus
time or versus the population predictions to test this
assumption. In addition to prediction-based evaluation,
methods can also be (Monte Carlo) simulation-based,
including, for example, visual predictive checks (VPCs),
and plots investigating whether the distribution of nor-
malized prediction discrepancies (NPD) follows a normal
distribution [128]. Superior to internal evaluation is
external evaluation, where the ability of a model to predict
data that were not used for model building is assessed.
When a separate dataset for external evaluation is not
available, a so-called cross-validation approach can be used
instead, where a dataset is split several times into a model
building and model evaluation dataset, and then, for
example, prediction errors are calculated [126].
5 Role of PKPD Modeling in Pediatric Trial
Design
PKPD modeling can be applied to various further aspects
of study design. For example, as briefly introduced above,
it can be used in the context of optimal design to identify
the most informative sampling schedule, number of sam-
ples per participant, and sample size; specialist software is
available to support these processes [129–132]. Optimal
design methods and concepts applied to pediatric PKPD
studies have recently been reviewed by Roberts et al. [133].
When designing PKPD trials it is essential to account for
patient acceptability and logistical factors in running the
trial. Simple designs may be preferable, where feasible,
providing they are scientifically sound [134], although
caution should be exercised when employing opportunistic
sampling to ensure methodological suitability for the
drugs/analytes being studied [135, 136]. PKPD modeling
can also incorporate knowledge regarding the expected
placebo effect (where relevant) and anticipated rates of
study attrition [137, 138]. Early engagement with children
and families (patient–public involvement) to help guide
decision making can provide valuable input to guide study
design and research ethics committees (Institutional
Review Boards) when reviewing protocols [139]. These
considerations are particularly important in certain settings,
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such as pediatric/neonatal intensive care, oncology, or
resource-limited environments, and the relevant context-
specific, ethical, and practical issues should be factored
into study design [140–143].
6 Role of PKPD Modeling in Dose Optimization
Strategies
Once drugs are in routine clinical use in pediatric patients,
there are further applications of PKPD modeling, which
have also been developing rapidly in recent years. As
mentioned above, model-based decision support strategies
can be used to guide TDM or dose individualization
approaches in patient populations where pharmacokinetic
variability is clinically important [101, 114, 144–150]. At
present, the availability of the necessary software and
expertise is highly variable, even in resource-rich settings,
but it is anticipated that these techniques will be more
frequently used in the clinic over the next 5–10 years.
Should adaptive licensing become commonplace in future
[103, 151, 152], then the importance of these dose opti-
mization concepts will be further reinforced.
7 Moving Forward in this Field
The importance of PKPD modeling in pediatric drug
development continues to grow, and it will clearly have a
pivotal role in clinical pharmacology research throughout
the lifecycle of medicinal products in the twenty-first
century. Ensuring relevant stakeholders in drug develop-
ment are familiar with the central tenets in PKPD modeling
will enhance successful applications of these methods to
improve efficiency in the drug development pipeline.
The scaling principles discussed in this review are
equally applicable to small molecules and biologics [153].
Initiatives to aid data and model warehousing, such as the
Drug Disease Model Resources (DDMoRe) collaboration
[154, 155], and standardization of trial conduct, reporting
and analysis methods [156–158], will hopefully lead to
greater potential for learning across compounds.
Growing recognition that personalized medicine incor-
porates all aspects of variability (including genetics) will
see expanding use of model-based TDM. There is also a
clear need to engage with the gene therapy clinical trials
community because the mathematics and statistics of dos-
ing regimen design, and assessing treatment impact on
disease progression, which have developed in clinical
pharmacology, are also highly relevant in this context.
8 Conclusions
PKPDmodeling will remain critically important in the design
and conduct of clinical pharmacology research in children,
particularly during drug development. Pediatric PK has now
moved on from the paradigm ‘children are not small adults’
towards recognition of how important parameters scale with
both size and age. Once appropriate functions for size and age
are added to a PK model, this allows their effects to be
delineated from other patient-specific factors such as severity
of disease state and organ dysfunction. Instead of using
complicated methods for scaling, which risks delivering
parameters that are difficult to interpret, we advocate one
standard approach for pediatric scaling of CL using a com-
bination of allometric weight scaling to account for size-re-
lated changes in CL, and a sigmoid function to describe age-
related maturation of CL. When parameterization for age and
size is standardized, comparison of parameters across studies
of the same or similar compounds is readily enabled. Due to
the heterogeneity of PD endpoints and regulatory guidance
allowing PK-only extrapolation in some cases, much less
attention has been paid to the scaling and maturation of drug
effects to date. Since PD endpoints are often easier to collect
than PK [152, 159], it is now time that the assumptions of
equal efficacy with similar exposure are challenged in all age
groups using PKPDmodeling in order to progress towards the
ultimate goal of truly optimized pediatric pharmacotherapy.
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